Oorja Bio:
Repair.
Reverse.
Remodel.
Redefining the Future of Fibrotic Disease
Leadership
Sujay Kango
Chief Executive Officer& Founder
Sujay Kango, B.S., MBA
Mr. Sujay Kango is an experienced executive with over 25 years in the pharmaceutical and biotechnology sector, spanning leadership roles in both public and private companies. He most recently served as President and Chief Executive Officer of Tmunity Therapeutics, which was acquired by Gilead Sciences in February 2023. Previously, he was Executive Vice President and Chief Commercial Officer of Acceleron Pharma, which was acquired by Merck & Co. for over $11.8 billion.
Mr. Kango has a proven track record in creating shareholder value, leading strategic transactions, licensing agreements, and capital raising in both private and public markets. He has had direct accountability for over $1 billion in product revenues and global P&L and has successfully built collaborations between biotech and large pharmaceutical companies, including Acceleron and BMS, AbbVie and Infinity, and Onyx and Bayer. Earlier in his career, he held leadership positions at AbbVie, Infinity Pharmaceuticals, Onyx, and Merck & Co.
He earned a B.S. in Microbiology and an M.B.A. from McNeese State University.
Janethe Pena
Chief Medical Officer & Founder
Janethe de Oliveira Pena, MD, PhD
Dr. Janethe de Oliveira Pena is a clinical development leader with 14 years of experience advancing innovative therapies in rare and serious diseases, including pulmonary hypertension, interstitial lung disease, and systemic sclerosis. She led the high‑profile sotatercept program from early phase 2 through phase 3 studies and 2023 BLA submissions at Merck & Co., following its $11.8 billion acquisition of Acceleron Pharma. Sotatercept was subsequently recognized as the #1 most valuable R&D project of 2023 by Evaluate Pharma.
Dr. de Oliveira Pena has guided programs through complex global regulatory pathways, securing Orphan Drug, Breakthrough Therapy, PRIME, and Priority Review designations, and has managed multidisciplinary teams spanning clinical operations, regulatory affairs, pharmacovigilance, and medical affairs. Earlier in her career, she was an associate professor of immunology at the Federal University of Uberlândia, where she led the graduate program in immunology.
She earned an M.D. from the Federal University of Uberlândia and a Ph.D. from the Federal University of São Paulo, and completed postdoctoral fellowships at Harvard Medical School and Washington University School of Medicine.
Connie Coulomb
Chief Business Officer& Founder
Connie Coulomb, B.S., MBA
Ms. Connie Coulomb brings over 25 years of biopharma leadership, driving transformative business development, licensing, and global commercialization strategies across Merck, Amgen, Biogen, and Onyx Pharmaceuticals. She has spearheaded market expansion and high‑impact growth initiatives, accelerating portfolio performance and market entry worldwide.
Ms. Coulomb played a pivotal role in landmark transactions, including representing RemeGen in its $2.6 billion out‑licensing of disitamab vedotin to Seagen, the largest out‑licensing deal by a Chinese company to date. At Biogen, she served as Divisional Vice President and General Manager, leading a $1.5 billion U.S. multiple sclerosis portfolio, and at Amgen, she directed commercial operations across 35 countries, including the global launch of Repatha in the United States. She has also advised Pfizer, Gilead, Genentech, and the Bill & Melinda Gates Foundation, advancing initiatives in global health and market strategy.
She holds an MBA from Stanford Graduate School of Business and dual advanced degrees in Business Management and Accounting from the University of Buenos Aires, graduating Magna Cum Laude.
Investor
